# Asmeton minimizes dry cough and diaphragmatic contraction during pulsed-field ablation of atrial fibrillation: a clinical prospective randomized study

**Authors:** Huixing Liu, Yan Zhang, Huafen Liu, Wei Liu, Zhuo Wang, Can Leng, Gangjie Xie, Jiahao Zhao, Jinlin Huang, Lei Huang, Yuzhi Lu, Hongwei Zhang, Songyun Wang, Hong Jiang

PMC · DOI: 10.3389/fphys.2025.1702254 · Frontiers in Physiology · 2026-02-18

## TL;DR

A new method using asmeton reduces dry cough and diaphragmatic contractions during heart ablation procedures under sedation.

## Contribution

Asmeton significantly reduces dry cough and diaphragmatic contraction during pulsed-field ablation under conscious sedation.

## Key findings

- Dry cough scores were reduced by 73.1% in the asmeton group compared to the control group.
- Severe diaphragmatic contraction incidence dropped to 0% in the asmeton group.
- Asmeton reduced moderate-to-severe dry cough and diaphragmatic contraction severity during ablation.

## Abstract

Pulsed-field ablation (PFA) is a novel ablation modality with promising outcomes for atrial fibrillation therapy. However, PFA might lead to dry cough and diaphragmatic contraction, especially under conscious sedation. We aim to explore a novel approach to reduce dry cough and diaphragmatic contraction during PFA procedures performed under conscious sedation.

A total of 16 patients who underwent PFA pulmonary vein isolation under conscious sedation were divided into the asmeton (with preprocedure asmeton) and control groups. A scoring system was developed to assess dry cough and diaphragmatic contraction.

A total of 608 ablations and 893 ablations were performed in the control and asmeton groups, respectively. The dry cough score (P = 0.045) in all pulmonary veins was significantly reduced by 73.1% in the asmeton group in comparison with the control group. The proportion of medium-to-high dry cough incidences decreased from 12.2 ± 10.4% in the control group to 1.8 ± 3.7% in the asmeton group (P = 0.027). The diaphragmatic contraction score in the asmeton group was 37.5% lower than that in the control group, and the proportion of severe diaphragmatic contraction incidences was significantly reduced from 2.8 ± 8.4% in the control group to 0.0 ± 0.0% in the asmeton group (P = 0.006).

Asmeton might eliminate moderate-to-severe dry cough and reduce the severity of diaphragmatic contraction during pulmonary vein isolation under conscious sedation ablation.

## Linked entities

- **Diseases:** atrial fibrillation (MONDO:0004981)

## Full-text entities

- **Genes:** IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}
- **Diseases:** Cough (MESH:D003371), head swelling (MESH:D006258), PFA (MESH:D007922), PV (MESH:D011087), AF (MESH:D001281), pain (MESH:D010146), respiratory diseases (MESH:D012140), tremors (MESH:D014202), CL (MESH:D002971), headache (MESH:D006261), inflammatory (MESH:D007249), fatigue (MESH:D005221), chest pain (MESH:D002637), heart rupture (MESH:D006341), abnormal diaphragmatic contractions (MESH:D006548), LSPV (MESH:D000071078), stroke (MESH:D020521), allergic (MESH:D004342), respiratory disorders (MESH:D012131), heart failure (MESH:D006333), cardiac arrhythmia (MESH:D001145)
- **Chemicals:** benzodiazepines (MESH:D001569), Asmeton (-), methoxyphenamine (MESH:C005157), aminophylline (MESH:D000628), carbonate (MESH:D002254), methoxylamine (MESH:C005214), noscapine (MESH:D009665), NOAC (MESH:C065145), chlorphenamine maleate (MESH:D002744), fentanyl (MESH:D005283)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** C-8  C

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12956715/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12956715/full.md

## References

21 references — full list in the complete paper: https://tomesphere.com/paper/PMC12956715/full.md

---
Source: https://tomesphere.com/paper/PMC12956715